Date post: | 27-Jul-2015 |
Category: |
Investor Relations |
Upload: | redchip-companies-inc |
View: | 46 times |
Download: | 1 times |
Forward Looking StatementsAll statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Akers Biosciences, Inc. (ABI or the Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov.
Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business.
The Company disclaims any intent or obligation to update these forward-looking statements.
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
2
Introduction
• Bringing diagnostics to the point-of-care
• Multiple core products with blockbuster potential
• Faster, better diagnostics which take costs out of the healthcare system
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
3
• ABI sells the only FDA cleared rapid test to detect heparin allergies; competes with expensive, slow turn-around laboratory tests
• 25 million patients in US and EU receive heparin annually
• 4 million tests performed annually in laboratories in US which could be replaced with PIFA
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
STAT Point-of-Care
5
Only combined rapid test for Total, HDL and LDL cholesterol
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
6
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Research & Discovery
Clinical Development
Commercial Development
Launch & Market Entry
Pipeline products
Dengue Fever
Troponin I
Chlamydia
Malaria
Diabetic Ketoacidosis
COPD
Lung Cancer
Asthma
7
Developing the world’s first rapid diagnostic assays for Lung CancerAsthma & COPD through breath
• LUNG CANCER: > 1.6 million people diagnosed each year
• ASTHMA: Up to 15% of a country’s population may have Asthma
• COPD: 1 billion smokers at risk for COPD
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
8
Improving how diabetics manage Ketoacidosis
• Type 1, and some Type 2, diabetics are at risk for developing ketoacidosis (blood acid build-up)
• 3 million type 1 diabetics in US
• Reduces healthcare costs by decreasing the need for hospital visits and expensive lab testing
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
9
Milestones
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
• Enhance sales and marketing capabilities
• Create more international alliances: Konica Minolta, Joint Venture in China
• Expand US and International distribution of PIFA PF4 products
• Launch international distribution of Breath Ketone “Check” and expand Tri-Cholesterol “Check”
• Establish US distribution channels for Tri-Cholesterol “Check”, METRON and VIVO
10
• New healthcare environment demands cost-containment
• Multiple products with blockbuster potential, some already selling
• Substantial new product pipeline with mass market potential
• Company underpinned by multiple valuable technology platforms
Summary
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
11
Profit and Loss
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Nine Months Fiscal YearEnded Sep 30 Ending Dec 31
2014 2013 2012
Revenue $2,980,389 $3,577,851 $1,564,101
Gross Profit 2,072,513 1,664,007 556,150
Administrative Expenses 2,497,485 1,524,626 1,493,707
Sales & Marketing Expenses 966,357 684,720 638,732
Research & Development Expenses 686,376 1,006,800 900,380
Operating Loss (2,271,634) (1,526,773) (2,725,228)
Net Loss (2,214,915) (1,526,773) (2,557,820)
13
Balance Sheet Overview
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
As of
Sep 30, 2014 Dec 31, 2013
Total Assets 16,782,653 6,075,622
Total Liabilities 1,054,944 1,953,388
Total Equity 15,727,709 4,122,234
14
Capitalization Structure
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Sep 30, 2014Shares
Common Shares 4,954,837
Directors & Officers Options – Exercise Price of $5.50 115,000
Key Employee Options – Exercise Price of $3.98 60,000
Warrants – Exercise Price of $71.76 1,989
Total – Fully Diluted 5,131,826
15
Experienced Board
Raymond F. Akers, Jr. Ph.D.Founder, Executive Chairman of the Board (Director)• 30+ years in medical diagnostics; founded ABI in 1989• Invented most of ABI’s products and technologies; numerous patents• Ph.D. in Neurochemistry, Northwestern University
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Gavin E.D. MoranNon-Executive Director• Extensive experience in trading, finance and marketing• Trading roles at Shell International, Trafigura Ltd, and since April 2010, beneficial shareholder at Sono International Ltd
Brandon T. KnoxNon-Executive Director• Experience in corporate finance and financial management• Currently wealth advisor at Raymond James
Thomas J. KnoxNon-Executive Vice Chairman• Expertise in health care and finance• Former CEO of United Healthcare of Pennsylvania; Former Chairman of the Board and Chief Executive Officer of Fidelity Insurance
Group, Inc.• Currently Chief Executive Officer of Knox Consulting Group, Chairman of ORB Automotive Corporation, Ltd
16
COPYRIGHT® 2014 | NASDAQ: AKER | LSE: AKR
Product SummaryCommercial DevelopmentClinical Development Launch & Market Entry
Asthma
COPD*
*Chronic Obstructive Pulmonary Disorder
Diabetic Ketoacidosis
Commercial DevelopmentClinical Development Launch & Market Entry
Hep B / Hep C
HIV 1 + 2
Lung Cancer
Syphilis / Gonorrhea
Dengue Fever
17